Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference

Sep 23, 2025 | Press Releases

CUPERTINO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in...

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Sep 19, 2025 | Press Releases

CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in...

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Sep 18, 2025 | Press Releases

CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in...

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025 | Press Releases

– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial- – Successful completion of two large randomized double-blind...

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Jun 26, 2025 | Press Releases

CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the...